Details for New Drug Application (NDA): 207325

NDA 207325 describes OXALIPLATIN, which is a drug marketed by Accord Hlthcare, Actavis, Actavis Totowa, Am Regent, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hospira Inc, Hospira Worldwide, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Qilu Pharm Hainan, Sandoz, Sun Pharm, and Teva Pharms, and is included in twenty-seven NDAs. It is available from eighteen suppliers. Additional details are available on the OXALIPLATIN profile page.

The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

Summary for 207325

Tradename:	OXALIPLATIN
Applicant:	Gland
Ingredient:	oxaliplatin
Patents:	0

Pharmacology for NDA: 207325

Suppliers and Packaging for NDA: 207325

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	207325	ANDA	Gland Pharma Limited	68083-176	68083-176-01	1 VIAL, SINGLE-USE in 1 CARTON (68083-176-01) / 10 mL in 1 VIAL, SINGLE-USE
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	207325	ANDA	Gland Pharma Limited	68083-177	68083-177-01	1 VIAL, SINGLE-USE in 1 CARTON (68083-177-01) / 20 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	50MG/10ML (5MG/ML)
Approval Date:	Feb 10, 2017	TE:	AP	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	100MG/20ML (5MG/ML)
Approval Date:	Feb 10, 2017	TE:	AP	RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INTRAVENOUS			Strength	200MG/40ML (5MG/ML)
Approval Date:	Oct 18, 2017	TE:		RLD:	No

Complete Access Available with Subscription